bionion的个人博客分享 http://blog.sciencenet.cn/u/bionion

博文

Osimertinib (AZD9291) is an oral, irreversible, and mutant-s

已有 2299 次阅读 2015-11-26 11:54 |系统分类:科研笔记| style, target, justify, title

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. [2]

AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. [2]

 

References

[1] Patent. 2013, WO2013014448 A1.

[2] Cross, et al. Mol Cancer Ther. 2013, 12, A109.




https://wap.sciencenet.cn/blog-2321593-938733.html

上一篇:Cimetidine, a histamine congener, competitively inhibits
下一篇:CL-387785 (EKI-785) is an irreversible, and selective EGFR i
收藏 IP: 58.32.204.*| 热度|

0

该博文允许注册用户评论 请点击登录 评论 (0 个评论)

数据加载中...

Archiver|手机版|科学网 ( 京ICP备07017567号-12 )

GMT+8, 2024-10-8 05:40

Powered by ScienceNet.cn

Copyright © 2007- 中国科学报社

返回顶部